TY  - JOUR
AU  - Sonke, Gabe S
AU  - Hart, Lowell L
AU  - Campone, Mario
AU  - Erdkamp, Frans
AU  - Janni, Wolfgang
AU  - Verma, Sunil
AU  - Villanueva, Cristian
AU  - Jakobsen, Erik
AU  - Alba, Emilio
AU  - Wist, Erik
AU  - Favret, Anne M
AU  - Bachelot, Thomas
AU  - Hegg, Roberto
AU  - Wheatley-Price, Paul
AU  - Souami, Farida
AU  - Sutradhar, Santosh
AU  - Miller, Michelle
AU  - Germa, Caroline
AU  - Burris, Howard A
PY  - 2017
DO  - 10.1007/s10549-017-4523-y
UR  - http://hdl.handle.net/10668/11714
T2  - Breast cancer research and treatment
AB  - Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2- advanced breast cancer. 668 postmenopausal women with HR+, HER2- advanced breast cancer and no prior systemic therapy for advanced disease...
LA  - en
KW  - Breast cancer
KW  - CDK inhibitor
KW  - Elderly
KW  - Endocrine therapy
KW  - Hormone receptor-positive
KW  - Ribociclib
KW  - Aged
KW  - Aged, 80 and over
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Letrozole
KW  - Middle Aged
KW  - Nitriles
KW  - Purines
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Triazoles
TI  - Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
TY  - research article
VL  - 167
ER  -